Foundations of opioid risk management

被引:111
作者
Katz, Nathaniel P.
Adams, Edgar H.
Benneyan, James C.
Birnbaum, Howard G.
Budman, Simon H.
Buzzeo, Ronald W.
Carr, Daniel B.
Cicero, Theodore J.
Gourlay, Douglas
Inciardi, James A.
Joranson, David E.
Kesslick, James
Lande, Stephen D.
机构
[1] Tufts Univ, Sch Med, Boston, MA 02111 USA
[2] Northeastern Univ, Boston, MA 02115 USA
[3] Anal Grp Inc, Boston, MA USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Analges Res, Newton, MA USA
[6] Inflexxion Inc, Newton, MA USA
[7] Covance Inc, Princeton, NJ USA
[8] BuzzeoPDMA Inc, Richmond, VA USA
[9] Washington Univ, St Louis, MO USA
[10] Univ Toronto, Toronto, ON, Canada
[11] Univ Delaware, Newark, DE USA
[12] Univ Wisconsin, Madison, WI USA
[13] Interact Forums Inc, Bala Cynwyd, PA USA
关键词
opioid analgesics; risk management; epidemiology; substance abuse; drug diversion;
D O I
10.1097/01.ajp.0000210953.86255.8f
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Increased abuse and diversion of prescription opioids has been a consequence of the increased availability of opioids to address the widespread problem of undertreated pain. Opioid risk management refers to the effort to minimize harms associated with opioid therapy while maintaining appropriate access to therapy. Management of these linked public health issues requires a coordinated and balanced effort among a disparate group of stakeholders at the federal, state, industry, practitioner, and patient levels. This paper reviews the principles of opioid risk management by examining the epidemiology of prescription opioid abuse in the United States; identifying key stakeholders involved in opioid risk management and their responsibilities for managing or monitoring opioid abuse and diversion, and summarizing the mechanisms currently used to monitor and address prescription opioid abuse. Limitations of current approaches, and emerging directions in opioid risk management, are also presented.
引用
收藏
页码:103 / 118
页数:16
相关论文
共 82 条
[1]  
*AM PAIN SOC, 2005, US OP TREATM CHRON P
[2]  
[Anonymous], 2004, RES 2003 NAT SURV DR
[3]  
[Anonymous], 2005, RES 2004 NAT SURV DR
[4]   Postmarketing surveillance for drug abuse [J].
Arfken, CL ;
Cicero, TJ .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S97-S105
[5]   Identifying and assisting the impaired physician [J].
Boisaubin, EV ;
Levine, RE .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2001, 322 (01) :31-36
[6]   Maximizing the value of electronic prescription monitoring programs [J].
Brushwood, DB .
JOURNAL OF LAW MEDICINE & ETHICS, 2003, 31 (01) :41-+
[7]   The art and science of risk management - A US research-based industry perspective [J].
Bush, JK ;
Dai, WS ;
Dieck, GS ;
Hostelley, LS ;
Hassall, T .
DRUG SAFETY, 2005, 28 (01) :1-18
[8]   Validation of a screener and opioid assessment measure for patients with chronic pain [J].
Butler, SF ;
Budman, SH ;
Fernandez, K ;
Jamison, RN .
PAIN, 2004, 112 (1-2) :65-75
[9]   A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States [J].
Cicero, TJ ;
Adams, EH ;
Geller, A ;
Inciardi, JA ;
Muñoz, A ;
Schnoll, SH ;
Senay, EC ;
Woody, GE .
DRUG AND ALCOHOL DEPENDENCE, 1999, 57 (01) :7-22
[10]   Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool [J].
Compton, P ;
Darakjian, J ;
Miotto, K .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (06) :355-363